Hong Kong Market Midday Commentary | Hang Seng Index Rises 1.19% in Morning Session; Innovative Drug Sector Gains

Shares of intelligent driving-related companies rallied collectively. The state has strengthened regulatory oversight on market access for intelligent connected vehicles, marking a turning point for institutionalized commercial implementation in the industry.

Zhitong FinanceJul 2 00:00 ET

Shares of innovative drug developers continued to rise, as payment reforms for innovative medicines accelerate, positioning pharmaceutical companies to enter a sustained period of earnings realization.

Shares of innovative pharmaceutical companies continued to rise. As of the time of writing, Simcere Pharmaceutical (02096.HK) was up 8.02% at HK$10.64; 3SBio (01530.HK) gained 7.58% to HK$18.17; Akeso (09926.HK) rose 6.81% to HK$94.05; and Innovent Bio (01801.HK) increased by 6.66% to HK$84.90.

Zhitong FinanceJul 1 23:25 ET

Here's Why We Think 3SBio (HKG:1530) Is Well Worth Watching

Simply Wall StJun 28 22:48 ET

3SBio Inc. (HKEX: 1530) repurchased 4.046 million shares on June 26 at a cost of HK$64.3768 million.

3SBio Inc. (HKEX: 1530) announced that on June 26, 2026, it repurchased 4.046 million shares at a cost of HK$64.3768 million.

Zhitong FinanceJun 26 07:08 ET

On June 25, 3SBio Inc. (HKEX: 1530) repurchased 3.4615 million shares at a cost of approximately HK$55.3752 million.

3SBio Inc. (HKEX: 1530) announced that on June 25, 2026, the company repurchased 3.4615 million shares at a total cost of approximately HK$55.3752 million, at a price range of HK$15.9 to HK$16 per share.

Zhitong FinanceJun 25 08:29 ET

3SBio Inc. (HKEX: 1530): KPMG Appointed as New Auditor

3SBio Inc. (HKEX: 1530) announced that Ernst & Young has resigned as the company's auditor upon the expiration of its term at the conclusion of the 2026 annual general meeting of shareholders and will not seek reappointment.

Zhitong FinanceJun 25 06:04 ET